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Abstract 
The directly compressible floating-bioadhesive tablets of tramadol were 
formulated using varying amounts Carbopol 971P (CP) and hydroxy-
propylmethyl cellulose (HPMC), along with other requisite excipients. In vitro 
drug release profile, floatational characteristics and ex vivo bioadhesive 
strength using texture analyzer were determined, and systematically optimized 
using a 3
2 central composite design (CCD). The studies indicated successful 
formulation of gastroretentive compressed matrices with excellent controlled 
release, mucoadhesion and hydrodynamic balance. Comparison of the 
dissolution profiles of the optimized formulation, with optimal composition of 
CP:HPMC :: 80.0:125.0, with that of the marketed controlled release formulation 
other indicated analogy of drug release performance with each other. Validation 
of optimization study using eight confirmatory experimental runs indicated very 
high degree of prognostic ability of CCD with mean ± SEM of −0.06% ± 0.37. 
Further, the study successfully unravels the effect of the polymers on the 
selected response variables. 
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Introduction 
Amongst various routes to deliver drugs, oral intake has unambiguously been the most 
sought after by the patients and manufacturers alike. Using the conventional oral dosage 
forms several drugs have to be administered quite frequently (i.e., 2–4 times-a-day) 
resulting, therefore, in high fluctuation in plasma drug levels causing saw-tooth kinetics. 
Controlled release (CR) systems are designed primarily for reducing the frequency of 
administration by regulating the drug concentration in the target tissue, ensuring patient 
compliance and consequently improving the efficacy of drugs [1,  2]. However, the 
development of a CR drug delivery system (DDS) is precluded by its inability to restrain 
and localize it within the desired region of gastrointestinal (GI) tract, and the highly variable 
nature of gastric emptying process [3]. 
The DDS can improve the controlled delivery of the drugs exhibiting an absorption window 
by continuously releasing the drug for a prolonged period before it reaches the absorption 
site, thus ensuring its optimal bioavailability [4, 5]. Various approaches including floating 
systems, bioadhesive systems, swelling and expanding systems and high density systems 
have been successfully employed to improve the gastric residence time of DDS [6, 7]. 
Though highly efficient for gastroretention, the floating systems suffer from a major 
disadvantage that they are effective only when the fluid level in the stomach is sufficiently 
high. However, as the stomach empties and the tablet is at the pylorus, the buoyancy of 
the dosage form may be impeded. This serious limitation can be overcome by making the 
floating system eventually adhere to the mucous lining of the stomach wall [8]. Floating 
and bioadhesive DDS, thus, offer the advantages of increased gastric residence, leading 
to improved bioavailability of drugs esp. with narrow absorption window [8, 9]. 
Tramadol is a synthetic codeine analogue and weak μ-opoid receptor agonist having an 
immense potential in analgesia. A specific absorption window limited only to the upper part 
of the small intestine coupled with high frequency of drug administration (4–6 hourly), 
small dose (50–100 mg) and short biological half-life (6–8 h) rationally call for the 
development of its gastroretentive CR product. Highly soluble and permeable, this drug 
can be safely regarded as a BCS class I therapeutic agent.  
Modern optimization techniques using experimental designs are a vital aid to the 
formulator, as they help in developing the best possible formulation under a given set of 
conditions, thus saving considerable time, money and developmental effort [10, 11]. Also 
these systematic techniques are known to provide a depth of understanding and ability to 
explore and defend the ranges for varied formulation and processing factors. Central 
composite design (CCD), in this regard, has been frequently employed for the optimization 
of gastroretentive systems [12, 13]. Hence, the present investigation aims at developing 
oral CR floating- bioadhesive matrices of tramadol hydrochloride, optimized using a CCD. 
Materials 
Tramadol HCl was provided ex gratis by M/s Alkem Laboratories Ltd., Mumbai, India and 
Sun Pharma Ltd., Mumbai, India. Methocel (Hydroxypropylmethyl cellulose, HPMC 
K100LV) and Carbopol 971P (CP) were obtained as the gift samples form M/s Panacea 
Biotec Ltd., New Delhi, India and M/s Noveon Pharmaceuticals, USA, respectively. Avicel 
PH 101 (Microcrystalline cellulose, MCC) and magnesium stearate (MST) were obtained   Formulation Optimization of Hydrodynamically Balanced Oral Controlled Release Bioadhesive …  305 
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from M/s Signet Chemical Corporation, Mumbai, India, and M/s Loba Chemie Ltd., 
Mumbai, India, respectively. Porcine gastric mucosa for determining bioadhesive strength 
was obtained from a local slaughter house of Chandigarh, India. All other chemicals and 
reagents used were of analytical grade, and were used as received. 
Methods 
Screening of polymers and their levels 
During preliminary studies, six polymers viz. CP 934P, CP 971P, HPMC K15M, 
HPMC  K100LV, NaCMC and Xanthan gum were investigated for formulating oral CR 
floating-mucoadhesive matrices of tramadol hydrochloride. Tablets were prepared using 
each of these polymers, with the ratio of tramadol to polymer kept as 1:2 to 1:4. 
Later on, depending upon the results obtained, the polymer blend containing the two 
polymers viz. CP 971P and HPMC K100LV was selected for further investigation. Besides 
these polymers, the other constituent employed in variable amounts was MCC. To 
evaluate the inertness of MCC on drug release of tramadol, the drug release of formulation 
without MCC was compared with formulation containing the maximum amount of MCC 
employed. The initial study to screen suitable polymer combinations of each blend was 
carried out using the formula shown in Table 1. 
Tab. 1.  General composition of tramadol hydrochloride matrices during initial studies 
Ingredient Amount  (mg) 
Tramadol hydrochloride  100 
CP 971P  100–150 
HPMC K100LV  150–200 
Magnesium stearate  5 
Microcrystalline cellulose   q.s. to 400 
 
Formulation of tablets as per the experimental design 
Tab. 2.  Composition of gastroretentive tramadol tablets 
Ingredient Amount  (mg) 
Tramadol hydrochloride  100 
Carbopol   80–160 
Hydroxypropyl meyhyl cellulose  125–175 
Magnesium stearate  5 
Microcrystalline cellulose q.s. 
 
Different tablet formulations of tramadol HCl were formulated using varying amounts of the 
polymers (i.e., CP and HPMC), MST as glidant and lubricant, and MCC as an inert diluent. 
Table 2 enlists the various compositions employed during the study. Prior to use, tramadol 
and the polymers, viz. CP and HPMC were screened through # 80 mesh sieve (size: 
180 µm), while MCC and MS were screened through # 120 mesh sieve (size: 125 µm). All 306 B.  Singh  et al.:  
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the materials were accurately weighed and mixed intimately in a polythene bag for 10 
minutes. The blended mix was subsequently compressed into 440 mg tablets using flat-
faced round punches (12.8 mm diameter) fitted to a single-punch tablet compression 
machine (M/s Cadmach, Ahmedabad, India).  
Experimental Design 
A central composite design (CCD) for two factors at three levels each (with α=1), 
equivalent to a 3
2 factorial design [14], was selected to optimize varied response variables. 
The two factors viz. CP (i.e., polymer X1) and HPMC (i.e., polymer X2) were varied in the 
polymer blends, as required by the experimental design, and the factor levels suitably 
coded (Table 3). The amount of MS was kept as constant at 5 mg, while MCC was 
employed as a diluent in a sufficient quantity to maintain a constant tablet weight of 440 
mg. Amount of drug released in 16 h (rel16h), time taken to release 75% of drug (t75%), 
bioadhesive strength (ρ) and buoyancy time (Tb) were taken as the response variables. 
Tab. 3.  Factor Combinations as per the Chosen Experimental Design 
Coded Factor levels  Formulation 
code 
Experimental 
Trial No.  X1  X2 
E 1  −1  −1 
F 2  −1 0 
G 3  −1 1 
H 4  0  −1 
I 5  0  0 
J 6  0  1 
K 7  1  −1 
L 8  1  0 
M 9  1  1 
      
Translation of coded levels in actual units 
Coded Level  −1 0  1 
X1: CP (mg)  80  120  160 
X2: HPMC (mg)  125  150  175 
 
Tablet Assay and Physical Evaluation  
Ten tablets were pulverized. A quantity of powder equivalent to 20 mg of tramadol was 
shaken with 60 ml of methanol for 10 min. The resulting suspension was heated to 60 °C 
and shaken for 15 minutes. The contents were cooled and diluted to 100 ml with methanol 
and filtered (Whatman
® grade 597 filter paper, M/s Whatman International Ltd., Kent, UK). 
Spectrophotometric absorbance of the filtrate was measured at a λmax of 273 nm using a 
double beam UV/VIS spectrophotometer (Geaesys 6, M/s Thermo Fisher Scientific, 
Waltham, USA). The content of tramadol was determined using a previously constructed 
standard calibration plot, taking molar extinction coefficient as 2098.6. 
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Tablets were also evaluated for hardness using an electronic hardness tester (EH-01P, 
M/s Electrolab Instruments, Mumbai, India, n = 6), friability using Roche friabilator (M/s 
Tropical Lab Equipment, Mumbai, India, n = 6), weight variation using Analytical balance 
(AE 240, M/s Mettler Toledo, Greifensee, Switzerland, n = 10), and thickness using Vernier 
Callipers (M/s Baker Gauges Ltd., Pune, India, n = 10).  
In Vitro Drug Release Studies 
Dissolution studies were carried out on all the tablet formulations in triplicate, employing 
USP XXX [15] paddle method (Apparatus 2, M/s Pharma Test Apparatebau AG, Hainburg, 
Germany) at 50 rpm and 37 ± 0.5 °C, using simulated gastric fluid (SGF) pH 1.2 without 
pepsin as the dissolution medium. An aliquot of sample was withdrawn periodically at 
suitable time intervals and volume replaced with an equivalent volume of plain dissolution 
medium. Samples were analyzed spectrophotometrically at 271 nm. Drug release data 
obtained during in vitro dissolution studies were analyzed using ZOREL software [16] with 
in-built provisions for applying the correction factor for volume and drug losses during 
sampling [17]. Drug release data were fitted into Korsemeyer-Peppas model for swollen 
matrices [18, 19], as described by Eq. 1. 
Eq. 1.  
n n t t k t k
M
M 2
2 1 ⋅ + ⋅ =
∞
 
where, Mt is amount of drug released at time ‘t’, M∞ is amount of drug released at an 
infinite time, k1 is the magnitudinal contribution of diffusion mechanism, k2 is the 
magnitudinal contribution of polymer relaxation mechanism, and n is the Fickian diffusion 
coefficient. Based on the phenomenological analysis, the type of release, i.e., whether 
Fickian, non-Fickian (anomalous) or zero-order, was predicted. The value of t75% was 
calculated using Stineman interpolation option of the GRAPH 2.0 software (M/s Micromath 
Inc., Saint Louis, USA). 
Bioadhesion Studies and Duration of Buoyancy 
Porcine gastric mucosa was utilized as the model membrane for ex vivo bioadhesive 
strength determination of various formulations. The mucosal membrane was excised by 
removing the underlying connective tissue and was placed on the base of Texture Profile 
Analyzer (TAX TEE 32, M/s Stable Microsystems, Surrey, UK). A tablet was attached to 
the stainless steel probe fixed to the mobile arm of the texture analyzer. The area of 
contact of mucosa was moistened with 50 μL of SGF. The mobile arm was lowered at a 
rate of 0.5 mm/s
 until a contact with the membrane was made. A contact force of 10 g was 
maintained for 300 s, after which the probe was withdrawn from the membrane. The peak 
detachment force was recorded as a measure of bioadhesion.  
Determination of Buoyancy Duration  
The duration for which the formulation floats in the dissolution medium, in the upper one-
third of the dissolution vessel, was determined periodically after every 15 min, by careful 
visual observation during the dissolution run [20]. 
Determination of Specific Gravity  
The specific gravity of tablets was determined by displacement method, using benzene as 308 B.  Singh  et al.:  
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a displacing medium [21]. A plethysmometer was employed to measure tablet density. 
Firstly, the instrument was calibrated using benzene (density: 0.8723 g/cc) for its 
volumetric capacity. Benzene was filled up to a mark in the capillary of the instrument. 
Subsequently, five tablets of known mass were dropped in wider mouth of the 
plethysmometer. The system was kept undisturbed for 1 min to let benzene displace the 
air in the pores of the tablets. After that, the displacement in the volume of benzene in the 
side capillary was noted. Knowing the weight and volume occupied by the tablets, density 
of five tablets was determined. 
Optimization Data Analysis and Validation of Optimization Model 
The response variables which were considered for systematic DoE optimization included 
t75%, rel16h, Tb and ρ. For the studied design, the MLRA method was applied to fit full 
second-order polynomial equation with added interaction terms to correlate the studied 
responses with the examined variables using Design expert ver. 6.0.10 software (Stat-
Ease, Minneapolis, USA). The polynomial regression results were demonstrated for the 
studied responses. Finally, the prognosis of optimum formulation was conducted using a 
two-stage brute force technique using MS-Excel spreadsheet software. First, a feasible 
space was located and second, an exhaustive grid search was conducted to predict the 
possible solutions. The region of optimality was also ratified using overlay plots, drawn 
using the Design Expert
® software. Eight formulations were selected as the confirmatory 
check-points to validate RSM [5,  20,  22]. The observed and predicted responses were 
critically compared. Linear correlation plots were constructed for the chosen eight 
optimized formulations (CP:HPMC :: 80:125, 92.8:129, 140.8:149.75, 137.6:134, 123:166, 
118.4:169, 112:175, 126.4:175). The residual graphs between predicted and observed 
responses were also constructed separately, and the percent bias (= prediction error) was 
calculated with respect to the observed responses.  
Comparison of Drug Release with Marketed Formulation 
Drug release profile of the optimized formulations was compared with two marketed 
brands of once-a-day formulations, Tramazac
TM TC and Dolfre
TM SR, each containing 100 
mg of tramadol hydrochloride per tablet. 
Results and Discussion 
Selection of Polymers and Their Levels 
Six polymers viz. two grades of CP (i.e., CP 934P and CP 971P), HPMC (i.e., K15M and 
K100LV), sodium CMC and xanthan gum were selected for the preliminary studies, owing 
to their reported potential of release rate controlling ability, bioadhesive strength, non-
toxicity, non-irritancy, stability at GI pH and compatibility with drug. [23–25].  
Dissolution parameters of all the six selected polymers were studied by formulating them 
into tablet dosage forms containing varying drug: polymer ratios ranging between 1:2 and 
1:4. Out of all the polymers, CP 971P was found to be the most promising in regulating the 
drug release profile, followed by xanthan gum, sodium CMC, CP 934P, HPMC K15M and 
HPMC K100LV, as revealed by the high values of t70% associated with them. The high 
potential of CP in controlling drug release and imparting bioadhesive characteristics to the 
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tablets of atenolol [12], diltiazem HCl [26] and hydralazine HCl [5]. Further, the 
compressed matrices formulated with HPMC K100LV, HPMC K15M and sodium CMC 
were found to be buoyant at all the studied levels with the order of floating time as: HPMV 
K100LV > HPMCK15M >> sodium CMC. The results are in consonance with earlier 
literature findings reporting high floatation potential of these cellulosic polymers [27].  
The lowest percentage of the hydrophobic substituents (methoxyl group) and the highest 
amount of hydrophilic substitution (hydropropoxyl) impart Methocel K series with the 
fastest rate of hydration, as compared to the E and F series. Also, it is conceivable that for 
highly soluble drugs, an inadequate polymer hydration rate may lead to significant dose 
dumping due to quick penetration of fluids into tablet core. Hence, amongst the various 
substitutions types, the rapidly hydrating HPMC 2208 (Methocel K) is considered ideal for 
regulating the release of tramadol hydrochloride. Higher viscosity grades like Methocel 
K15 and K15CR were deemed unsuitable, as these usually yield drug blood levels in sub-
therapeutic range. Moreover, literature documents that the low-viscosity grades (e.g., 
HPMC K100LV) were found to be more beneficial than high-viscosity ones (e.g., HPMC 
K4M, HPMC K15M) in improving the floating properties [27]. For further product 
development studies, therefore, HPMC K100LV rather than HPMC K15M was chosen. 
The successful use of the polymer combination of CP and HPMC has already been 
documented in various literature reports in attaining excellent CR characteristics 
[5, 8, 12, 28]. Further, a combination of ionic polymer (like CP) and nonionic polymer (like 
HPMC) is known to provide the formulation with controlled drug release and/or desired 
mucoadhesive properties [26, 29]. 
For preliminary batch of tablets, drug release, as discerned from t75% values, was found to 
be better extended with increase in levels of either polymer. However, rel16h was found to 
be less than 89% in all the cases. Hence, it was planned to investigate levels of factors 
(80–160 mg for CP and 125–175 mg for HPMC), different from the ranges studied during 
pre-optimization studies (100–150 mg for CP and 150-200 mg for HPMC). Buoyancy time 
was found to decrease with increase in CP content, while reverse was the trend with 
increasing HPMC content. 
Selection of Other Excipients 
Water insoluble and water immobile excipients like MCC and dibasic calcium phosphate 
have been employed with fruition as inert diluents while achieving CR [20]. In the present 
study, tablets prepared using dibasic calcium phosphate sank immediately to the bottom of 
the dissolution beaker ostensibly due to its high density (0.780g/cc). Therefore, MCC with 
lower density (0.337g/cc) was employed as a diluent in the current studies. Further during 
the preliminary studies, the drug release profiles of the formulations with maximum amount 
of MCC employed and without MCC were found almost to superimpose over each other 
(f1 = 84.9). 
Selection of concentration of MST as ~1% was based on earlier studies carried out in our 
laboratories as it was found to be the adequate concentration to attain good powder flow 
characteristics and die ejection [5,  12]. The same was ratified in our preliminary 
experimental studies with tramadol tablets, too. 
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Drug Content and Physical Evaluation 
The assayed content of drug in various formulations varied between 98.9% and 100.5% 
w/w with mean ± SD as 99.7 ± 0.5%. Tablet weights varied between 439.1 and 442.4 mg 
(440.8 ± 2.2 mg), and thickness between 3.2 and 3.4 mm (3.3 ± 0.1 mm). Tablets require a 
certain amount of strength or hardness, and resistance to friability, to withstand the mech-
anical shocks of handling during their manufacture, shipping and packaging. The hardness 
of a tablet is closely related to its disintegration time and dissolution, and eventually its 
drug release rate [30]. Tablet hardness monitoring, therefore, is especially important for 
drug products which possess real or potential bioavailability problems or those sensitive to 
altered dissolution release profiles as a function of the compressive force applied. 
Representative tablets tested from each batch possessed hardness values hardness 
values ranging between 52.98 N and 70.24 N (60.21 ± 4.2 N), indicative of adequate 
strength to provide good tablet disintegration and dissolution profiles and to prevent 
friability losses. All the tablets tested from each batch exhibited friability values ranging 
between 0.37% and 0.65% w/w (0.50 ± 0.14%), far less than the limit of 1% w/w, generally 
considered as acceptable by the official compendia [31, 32]. Marginal variation in tablet 
hardness and friability could be attributed only to the random causes, but not to the matrix 
composition. This absence of any significant inter- and intra-batch variability in tablet 
hardness, friability and thickness, ruled out any plausibility of any change in compression 
pressure, and consequently in drug dissolution. 
In Vitro Drug Release Studies 
Table 4 enlists various dissolution parameters computed for all the CR bioadhesive 
formulations. Summary of the dissolution parameters, indicated in Table 3, shows that the 
value of n varies between 0.4502 and 0.5719, delineating non-Fickian release behavior. 
The values of n show increasing trend with increase in HPMC content, even at higher CP 
levels. However at low levels of CP 971P, n seems to bear a nonlinear relationship with 
HPMC. The value of n decreases as HPMC increases from low to intermediate levels, but 
enhances with further increase in HPMC to high levels. The table also shows a rising trend 
in the values of n as the content of CP is increased with significant increase at the highest 
levels of CP. Overall, the current results seem to be in agreement with the previous 
findings indicating ambiguous relationship of n with change in polymer composition 
[12, 26]. As depicted in the table, the values of k followed a declining trend with increase in 
the amount of either polymer. 
Relatively much higher magnitude of k1 vis-à-vis k2 clearly show that the drug release was 
predominantly Fickian diffusion, with the contribution of polymer relaxation as nearly 
negligible. This is in consonance with the earlier findings that a mixture of HPMC with CP 
resulted in the reduction of polymer viscosity due to reduced hydration [5, 26, 33]. This 
reduction of viscosity could facilitate drug diffusion through polymer hydrogel. Table 3 
reveals that the overall rate of drug release tended to decrease with increase in concen-
tration of HPMC or CP. Similarly, the values of Rel16h decreased drastically with increase 
in the polymer content. As much as 18% of drug is retained in the matrix till 16 hours when 
the highest levels of both the polymers were employed. Plausibly, it can lead to apprecia-
ble diminution in the extent of drug absorption. Conversely, the values of t75% were found 
to enhance markedly from 7.12 h to 11.99 h from low to high levels of both the polymers.   Formulation Optimization of Hydrodynamically Balanced Oral Controlled Release Bioadhesive …  311 
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Tab. 4.   Overall dissolution parameters for all the floating-bioadhesive tablet 
formulations of tramadol prepared using different amounts of CP 971P and 
HPMC K100LV of polymer blend as per central composite design 
Code n  K  k1  k2  rel16h 
(%) 
t75%  
(h) 
Drug release rate  
(mg/h) 
(Mean ± S.D.) 
E  0.4572 0.2844 1.3439 −0.0035  91.76   7.12 9.25±8.93 
F  0.4502 0.2772 1.3329 −0.0045  88.75   8.44 8.88±8.76 
G  0.4626 0.2653 1.3160 −0.0019  87.76   8.73 8.75±8.65 
H  0.4745 0.2555 1.3037   0.0001  86.84   8.80 8.71±8.56 
I  0.4842 0.2483 1.2921   0.0028  87.18   9.15 8.62±8.25 
J  0.4889 0.2420 1.2828   0.0039  86.41 10.20 8.50±8.07 
K  0.5093 0.2298 1.2659   0.0080  86.04 10.58 8.36±7.54 
L  0.5366 0.2073 1.2306   0.0141  83.20 11.72 8.00±6.68 
M  0.5719 0.1890 1.2056   0.0198  81.91 11.99 7.73±6.06 
 
Bioadhesive Strength Determination 
A distinct increase in the bioadhesive strength is observed with an increase in the amount 
of either polymer (CP or HPMC), which is in agreement with literature [12, 26, 34, 35]. 
Hydrogels swell rapidly in contact with hydrated mucous membrane, resulting in reduced 
glass transition temperature and increased uncoiling along with an increased mobility of 
polymer chains [12]. This tends to increase the adhesive surface for maximum contact with 
mucin and flexibility for interpenetration with mucin. Although the maximum value of 
bioadhesive strength was attained at the highest levels of both the polymers, yet the effect 
of CP was found to be more pronounced than that of HPMC. The bar diagram for 
detachment force (Fig. 1) pictographically depicts the change in bioadhesive strength of 
tablets with a change in the polymer level(s). 
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Fig. 1.  Bioadhesive strengths of the formulations prepared as per experimental design 
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Buoyancy Time and Specific Gravity  
It is a well-documented fact that swelling is a vital factor to ensure floatation [36–38]. To 
obtain adequate floating, the balance between swelling and water acceptance must be 
restored [20]. Buoyancy time (Tb) of the tablets increased in a linear fashion with increase 
in HPMC content, owing ostensibly to swelling (i.e., hydration) of the hydrocolloid particles 
on the tablet surface, resulting ultimately in an increase in the bulk volume. The air 
entrapped in the swollen polymer maintains a density less than unity and confers buoyant 
character to these dosage forms. With increase in CP content, however, buoyancy time 
decreases in a linear trend, probably due to higher density of CP (1.76 g/cc) than that of 
HPMC (1.28 g/cc). The bar diagram for buoyancy time (Fig. 2) corroborates the significant 
positive and negative influence of HPMC and CP on floatation, respectively. But, it is of 
interest to mention that the presence of CP could possibly aid in retaining the tablet 
following oral ingestion within the stomach by assisting in the adhesion of the dosage form 
on the gastric wall, which in turn, may aid in enhancing the tablet gastric retention time 
[28]. Tablet density of all the formulations was found to be lower than the density of gastric 
contents (1.004 g/cc), which satisfies the major criterion for a dosage form to float [39, 40]. 
Rather on water absorption into the polymer matrix and subsequent swelling, the density 
of swollen but intact tablet is further going to reduce in magnitude. 
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Fig. 2.  Buoyancy time of the formulations prepared as per experimental design 
High degree of correlation was found between buoyancy time (Tb) and tablet density for all 
the formulations (r
2 = 0.9901). As tablet density decreases, buoyancy time increases in a 
linear fashion. This construes that floating tendency of the matrix formulation is an inverse 
function of its density. Hence, to estimate the effect of formulation factors on the floatation 
characteristics, buoyancy time (but not density), was taken as the response parameter. 
Analogously, MDT and t75% were also found to be highly correlated with each other 
(r
2=0.9739). And on the similar heels, t75% (and not MDT) was taken as response 
parameter to declare extended drug release  
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Exploration of Polymer Mechanism using RSM 
Quite high values of R
2 of the MLRA coefficients for all four responses, ranging between 
0.9853 and 1.0000, vouch high prognostic ability of the RSM polynomials. Seven 
coefficients (β1 to β7) were calculated with β0 representing the intercept, and β3 to β7, 
representing the various quadratic and interaction terms (Eq. 2). 
Eq. 2.  
2
1 2 7
2
2 1 6
2
2 5
2
1 4 2 1 3 2 2 1 1 0 Χ Χ Χ Χ Χ Χ Χ Χ Χ Χ β β β β β β β β Y + + + + + + + =  
Various response surfaces and contour plots are depicted in Fig. 3 to 6. Fig. 3a to 6a 
portray the 3-D response surface plots, while Fig. 3b to 6b are the corresponding 2-D 
contour plots for the studied response variables. Fig. 3a depicts quite linear increasing 
trend in the values of t75% with augmentation of CP, and nearly linear increasing trend with 
HPMC fractions. Nevertheless, the influence of CP is distinctly far more significant than 
that of HPMC, indicating that the former has better release sustaining properties for 
tramadol than the latter. The same is being confirmed from the corresponding contour plot 
(Fig. 3b) showing declining linear contour lines. Hence, the higher levels of CP have to be 
complemented with lower levels of HPMC and vice-versa to maintain the value of t75% at a 
constant level.  
 
(a) (b) 
Fig. 3.  (a) Response surface plot showing the influence of CP and HPMC on the value 
of t75% of floating-bioadhesive tablet formulations of tramadol;  
(b) the corresponding contour plot 314 B.  Singh  et al.:  
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Fig. 4a and 4b reveal a decline in the value of Rel16h with an increase in the concentration 
of each of the polymers, i.e., CP and HPMC, the influence of CP being much more 
pronounced. At low levels of HPMC, a distinct linear decreasing trend is followed with 
increase in CP levels.  
 
(a) (b) 
Fig. 4.  (a) Response surface plot showing the influence of CP and HPMC on the value 
of rel16h of floating-bioadhesive tablet formulations of tramadol;  
(b) the corresponding contour plot 
Nonlinear descending contour lines in Fig. 4b further elucidate that the variation in Rel16h is 
an enigmatic function of the polymer levels, the effect of HPMC being less significant. 
Fig. 5a shows nearly linear ascending patterns for the values of bioadhesive strength as 
the content of either polymer is increased, once again, the effect, being more prominent 
with CP than with HPMC. At high levels of the polymers, however, the response surface 
takes a slight curvilinear shape. Maximum bioadhesive strength was observable at the 
highest levels of both the polymers viz. CP and HPMC. The corresponding contour plot 
(Fig. 5b) also reveals nearly decreasing trend at all the factor levels. Nearly vertical 
contour lines corroborate that only CP influences the ρ values significantly. The results are 
in consonance with literature reports stating high contribution of carbomers in attainment of 
bioadhesive strength in hydrophilic matrices [5, 12, 28]. 
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(a) (b) 
Fig. 5.  (a) Response surface plot showing the influence of CP and HPMC on the value 
of ρ of floating-bioadhesive tablet formulations of tramadol;  
(b) the corresponding contour plot 
The response surface (Fig. 6a) vividly connotes that HPMC is contributing significantly 
towards attaining floating characteristics to the formulation. The higher levels of CP, on the 
other hand, were counter-productive in imparting the buoyant character to the drug 
delivery devices, as nearly linear decreasing trend in Tb is clearly discernible with 
increased CP levels. Further, the 3D plot also reveals that the positive influence of HPMC 
in achieving higher values of Tb is relatively less pronounced than the negative influence of 
CP on the same. The corresponding 2-D contour plot (Fig. 6b) also depicts a curvilinear 
ascending pattern for the values of buoyancy time (Tb) as HPMC content increases. 
Maximum value of buoyancy time is discernible at the highest levels of HPMC and the 
lowest levels of CP, while the converse is also true to attain the minimum. 
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(a) (b) 
Fig. 6.  (a) Response surface plot showing the influence of CP and HPMC on the value 
of Tb of floating-bioadhesive tablet formulations of tramadol;  
(b) the corresponding contour plot 
DoE Validation and Selection of Optimum Formulation 
Upon comparison of the observed responses with those of the anticipated ones, the 
prediction error varied between −6.9 and 5.4 % with overall mean ± SD as −0.06 ± 0.37%. 
Linear correlation plots (Fig. 7) drawn between the predicted and observed responses 
after forcing the line through the origin, also demonstrated high values of r (0.9819 to 
0.9981), indicating excellent goodness of fit in each case (p < 0.001). The corresponding 
residual plots show nearly uniform and random scatter around the mean values of 
response variables.  
The optimum formulation was selected by “trading off” various response variables and 
adopting the following maximizing criteria: t75% ≥ 7.1 h; rel16h > 89%; ρ > 8.0 g and Tb > 8.5 
h. Upon comprehensive evaluation of grid searches, the formulation (CP: 80.0 mg and 
HPMC: 125.0 mg) fulfilled the optimal criteria of best regulation of the release rate, floating 
and bioadhesive characteristics with t75% of 7.10 h, rel16h of 91.71%, ρ of 8.5 g and Tb of 
9.68 h. Thus, besides controlling drug release, the formulation has definite gastroretentive 
potential to retain the drug in the gastric environment and upper part of intestine.   Formulation Optimization of Hydrodynamically Balanced Oral Controlled Release Bioadhesive …  317 
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Fig. 7.  Linear and residual plots between observed and predicted values of (a) Rel16h, 
(b) t75%, (c) ρ, (d) Tb 318 B.  Singh  et al.:  
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Comparison of Release Performance with Marketed Brands 
Table 5 shows the comparison of dissolution parameters of the marketed brands with the 
optimized formulation. Complete drug release was observed at 24 h in all the three studied 
formulations.  
Tab. 5.  Comparison of release performance of the optimized formulation with marketed 
brands of tramadol hydrochloride  
Similarity Factor  Formulation t70% 
(h) 
Rel12h 
(%) 
Rel16h 
(%) 
MDT 
(h) 
n k 
8h 16h  24h 
Tramazac
TM TC  5.72  94.24  98.50  4.802 0.5407 0.2430  75.49
  70.16 70.97
Dolfre
TM SR   5.58  88.41  94.82  5.143 0.5378 0.2355  72.03 73.46 74.24
Optimized 
formulation  
5.76 88.15 91.71 4.920 0.4569 0.2848  –  –  – 
 
 
Fig. 8:   In vitro drug release profiles of the optimized formulation and the two marketed 
formulations. The inset shows the corresponding rates of drug release. 
Drug release from the optimized formulation at 12 h (88.15%) was found to be closer to 
that of Dolfre
TM SR (88.41%). Similarly, the release parameters like t70%, Rel16h, MDT, K, n 
were quite close to each other. Further, the values of similarity factor, f1,  at periodic 
intervals of 8 h of both the marketed formulations vis-à-vis the optimised formulation, 
ranged between 70.16 and 75.49, unambiguously corroborating the sameness of the 
release profiles. Fig. 8 portrays the respective release profiles of the marketed   Formulation Optimization of Hydrodynamically Balanced Oral Controlled Release Bioadhesive …  319 
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formulations (esp. Dolfre
TM SR) and optimized formulation superimposed over each other 
also indicating almost analogy of release performance with each other. Thus, the studies 
conclude successful development of gastroretentive CR formulation of tramadol capable of 
maintaining similar drug release profiles as observed with the marketed CR products and 
delivering the drug at its preferred site of absorption in the GI tract. 
Conclusions 
The fluctuation in plasma levels of the drug and low patient compliance due to this high 
frequency of administration can be overcome only by formulating it as a CR once-daily 
DDS. Accordingly, the present studies aimed at formulating tramadol into a gastroretentive 
floating-bioadhesive system, preferred due to its ability of retaining the DDS in GIT and 
improving bioavailability esp. for drugs exhibiting specific absorption window in GI tract. 
But it was a Herculean task to attain the required floatational properties and bioadhesive 
potential in the formulation using blends of polymers like carbomers and methylcelluloses 
because of the diverse nature of these polymers. Carbomers, though, are very 
bioadhesive but being heavier in density, are considered unsuitable to impart buoyant 
characteristics to the formulation. On the other hand, the lighter hydrophilic 
methylcelluloses impart floatation but are less effective as bioadhesives. Only systematic 
studies using DoE optimization could surmount this hiccup of balancing optimal floatation 
with bioadhesion using this polymer combination. The choice of experimental design, i.e., 
a 2-factor CCD, was found to be highly appropriate, as it can detect any non-linearity in 
factor-response relationship with minimal expenditure of developmental effort and time. 
The optimized formulation exhibited excellent CR, bioadhesive and floatational 
characteristics vouching the success of the experimental approaches followed. Besides 
identical drug release profile to that observed with the marketed CR formulations, the 
optimized formulation exhibited excellent floatational and bioadhesive properties too using 
a synergistic blend of effective and cost-effective polymers. Hence, the studies can be 
safely regarded as a platform technology in the manufacture of gastroretentive CR 
formulations of BCS class I drugs as generic products, where matching of the drug release 
profiles with that of the innovators’ is the major criterion. 
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